Spexin, a neuropeptide expressed both in the central and the peripheral nervous system, is an important regulator of feeding behaviour and gastrointestinal motility. It has been implicated in several metabolic diseases including type-II diabetes, non-alcoholic fatty liver disease and, most notably, obesity. It is thought that spexin administration may promote weight loss in humans, but the neuropeptide has had limited success due to its short half-life in serum (i.e., it leaves the body too quickly).
The present invention is a newly synthesized spexin cyclic analogues that have much longer half-lives in serum. An intravenous injection of these analogues in obese mice resulted in reduced food intake and weight loss with few side effects.
Technology Features, Specifications and Advantages
Our synthesized spexin cyclic analogues have much longer half-lives in serum, meaning that it won't leave the body too quickly. In our animal study, it has proved that the analogues are very effective as it can reduce food intake and promote weight loss with much lower side effects when comparing to other drugs.
The present invention can be potentially used for treating several metabolic diseases including type-II diabetes, non-alcoholic fatty liver disease and, most notably, obesity. Since these analogues can stay longer in the body, the frequency of drug intakes or even the dosage might be significantly reduced that can benefit the clients.
Our drug can reduce food intake and promote weight loss with much lower side effect.